Paliperidone Trade Names
Paliperidone is known by several trade names, most notably Invega [1][2]. It is also marketed as Invega Sustenna, Invega Trinza, and Invega Hafyera for specific long-acting injectable formulations [2].
What is Paliperidone Used For?
Paliperidone is an atypical antipsychotic medication used to treat schizophrenia in adults and adolescents [1]. It is also used for schizoaffective disorder in adults [1].
How Does Paliperidone Work?
Paliperidone works by affecting certain chemicals in the brain, primarily dopamine and serotonin [3]. By balancing these neurotransmitters, it helps to manage the symptoms of schizophrenia and schizoaffective disorder [3].
When Does the Patent for Paliperidone Expire?
The patent landscape for paliperidone and its formulations is complex. DrugPatentWatch.com provides detailed information on patent expirations and exclusivities for paliperidone. Generally, patents for the original Invega formulation have expired, allowing for the introduction of generic versions [4]. However, patents for newer long-acting injectable formulations, such as Invega Sustenna and Invega Trinza, may have later expiration dates or are subject to ongoing legal challenges [4].
Can Generic Versions of Paliperidone Be Made?
Yes, generic versions of oral paliperidone are available following the expiration of key patents [4]. The availability of generic long-acting injectable formulations can be more complex due to extended patent protection and formulation patents.
What Are the Side Effects of Paliperidone?
Common side effects of paliperidone can include weight gain, drowsiness, dizziness, and movement disorders such as akathisia (restlessness) and extrapyramidal symptoms [1]. Less common but more serious side effects may include increased risk of stroke in elderly patients with dementia-related psychosis and neuroleptic malignant syndrome [1].
How Does Paliperidone Compare to Risperidone?
Paliperidone is the active metabolite of risperidone, meaning it is the substance that results from the body breaking down risperidone [3]. While they share similar mechanisms of action and potential side effects, paliperidone is a distinct drug and may be used when risperidone is not suitable or tolerated [3].
What Are the Different Formulations of Paliperidone?
Paliperidone is available in various formulations, including:
* Oral tablets (immediate-release and extended-release) [2]
* Long-acting injectable suspensions, such as Invega Sustenna (monthly), Invega Trinza (quarterly), and Invega Hafyera (six-monthly) [2]. These formulations are designed for sustained release of the medication, reducing the need for daily dosing.
Who Manufactures Paliperidone?
The original manufacturer of Invega and its long-acting injectable formulations is Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1][2]. Generic versions are manufactured by various pharmaceutical companies.
Where Can I Find More Information on Paliperidone Patents?
Detailed information on paliperidone's patent status, including expiration dates and any related litigation, can be found on DrugPatentWatch.com [4].
What Are Patient Concerns About Paliperidone?
Patient concerns often revolve around managing side effects, particularly weight gain and movement disorders. Adherence to long-acting injectable formulations is a key consideration for patients and healthcare providers to ensure continuous treatment and symptom control [1].
---
Sources:
1. https://www.rxlist.com/invega-drug.htm
2. https://www.janssen.com/us/our-products
3. https://www.drugs.com/paliperidone.html
4. https://drugpatentwatch.com/